Quantitative phase imaging supported by Raman micro-spectroscopy for identifying and quantifying changes in myeloid cells treated with proteasome inhibitor

Abstract

Bortezomib is one of the most researched proteasome inhibitor drug in cancer cell research. Studying its effects, measuring and monitoring treatment response and effectiveness is a widely developing area in cancer research. The introduction of non-invasive measurement tools into the this research is a very important and desirable development, as it is a promising alternative to existing chemical tests. In our work we presented multimodal methodology connecting multiple non-invasive and label-free techniques to study effects of bortezomib on RPMI8226 cells. We connected digital holographic microscopy and holographic tomography with chemical specificity from Raman micro spectroscopy and we showed that treatment with bortezomib caused decrease of RI in the cells and their nucleolus and that changes in chemical compositions after treatment indicate cell apoptosis.